Syndax Pharmaceuticals Inc (SNDX) — 8-K Filings

8-K Filings (11)

• 8-K Filing — Dec 19, 2025
• Syndax Pharmaceuticals Files 8-K — Oct 24, 2025 Risk: low
  Syndax Pharmaceuticals, Inc. filed an 8-K on October 24, 2025, reporting other events and financial statements. The filing details the company's corporate infor
• Syndax Pharmaceuticals Announces Board and Executive Changes — Jun 26, 2025 Risk: medium
  Syndax Pharmaceuticals, Inc. announced on June 24, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company re
• Syndax Pharmaceuticals Elects New Director — May 16, 2025 Risk: low
  Syndax Pharmaceuticals, Inc. announced on May 12, 2025, a change in its board of directors. Specifically, Dr. Michael S. Brown has been elected as a Class II Di
• Syndax Pharmaceuticals Announces Board and Officer Changes — Dec 20, 2024 Risk: medium
  Syndax Pharmaceuticals, Inc. filed an 8-K on December 20, 2024, reporting changes in its board of directors and executive officers, including the election of ne
• Syndax Pharmaceuticals Files 8-K — Nov 18, 2024 Risk: low
  Syndax Pharmaceuticals, Inc. filed an 8-K on November 15, 2024, reporting other events and financial statements. The filing details the company's principal exec
• Syndax Pharmaceuticals Files 8-K — Nov 12, 2024 Risk: low
  Syndax Pharmaceuticals, Inc. filed an 8-K on November 12, 2024, to report other events and financial statements. The filing does not detail specific transaction
• Syndax Pharmaceuticals Enters Material Definitive Agreement — Nov 4, 2024 Risk: medium
  On November 4, 2024, Syndax Pharmaceuticals, Inc. entered into a material definitive agreement. The filing does not disclose the specific details of this agreem
• Syndax Pharmaceuticals Files 8-K — Aug 1, 2024 Risk: low
  Syndax Pharmaceuticals, Inc. filed an 8-K on August 1, 2024, reporting on its results of operations and financial condition, as well as filing financial stateme
• Syndax Pharmaceuticals Reports Director Changes and Officer Appointments — May 15, 2024 Risk: medium
  Syndax Pharmaceuticals, Inc. filed an 8-K on May 15, 2024, reporting on several key events that occurred on May 14, 2024. These include the departure of a direc
• Syndax Pharmaceuticals Appoints New CEO — Mar 18, 2024 Risk: medium
  Syndax Pharmaceuticals, Inc. announced on March 15, 2024, the appointment of Dr. Michael M. Morrissey as Chief Executive Officer, effective March 18, 2024. Dr.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX